ArticleCureus2026
Colorectal Cancer in Young Adults in Panama: Clinical, Molecular, and Epidemiological Characterization in a National Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset colorectal cancer (≤49 years) is rising worldwide, yet data from Central America are scarce. We characterized clinical, molecular, and therapeutic features, estimated overall survival, and identified independent prognostic factors in young adults with colorectal cancer in Panama.
methodsWe used a retrospective cohort (2020-2023) from two national oncology referral hospitals. Demographic, clinical, molecular (RAS, microsatellite instability-high), behavioral (tobacco, alcohol, body mass index), and treatment data were collected. Overall survival was estimated using the Kaplan-Meier method; multivariable Cox regression assessed prognostic factors. The statistical software Stata version 18 (StataCorp, College Station, TX, USA) was used for data analysis.
resultsWe included 242 patients (median age 44 years), 126 (52%) of whom were female. Stage III-IV comprised 172 patients (71%), and stage IV comprised 103 patients (47%). Rectal tumors accounted for 83 patients (35%). RAS mutation was detected in 63 patients (36% overall and 61.3% of evaluable stage IV cases) and microsatellite instability-high in 19 patients (7.8%). Risk factors included tobacco use in 31 patients (12.8%), alcohol intake in 73 patients (32%), and overweight/obesity in 108 patients (44%). The geographical areas with the highest population density in the country have the highest case percentages, such as the province of Panama, with 105 patients (43.7%). Median overall survival was 34 months; overall survival at one, three, and five years was 78%, 49%, and 32% (95% CI 19.4-47.0). In multivariable analysis, independent predictors of worse overall survival were stage IV at diagnosis (p=0.001), baseline Eastern Cooperative Oncology Group (ECOG) score ≥2 (p=0.008), poor differentiation (p=0.020), and recurrence (p=0.030).
conclusionsEarly-onset colorectal cancer in Panama presents predominantly at advanced stages and is associated with limited survival. Stage, functional status, histologic differentiation, and recurrence independently predict mortality. Findings underscore the need for earlier detection, access to molecular testing, and equitable delivery of modern therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.